Q-omics provides the consensus-scored CNPY1 profile across patient tissues and cancer cell-line models. CNPY1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CNPY1 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, CNPY1 RNA expression shows 6,571 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, KIRC, and STAD as cancer lineages where CNPY1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNPY1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNPY1 survival associations across molecular data types. CNPY1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNPY1 RNA expression–survival associations across cancer types. High CNPY1 expression shows unfavorable associations in ACC, KIRC, KIRP, LUAD, THCA and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CNPY1 RNA expression.
This table summarizes CNPY1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CNPY1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNPY1 shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, HNSC, LUSC and LUAD. The KIRC box plot shows higher CNPY1 RNA expression in tumor versus normal tissue (log2 FC = +0.097, t-test p < 0.001).
This table shows molecular features associated with CNPY1 in patient tissues and cancer cell lines. In patient samples, CNPY1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CNPY1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
